Finally, we must recall here that, among the previously cited molecules, the results of the NAVIGATOR trial on the use of tezepelumab (an antibody against TSLP) are promising for both asthma and CRSwNP, even though this drug is not at present approved for treating the latter condition [75]. Here, TSLP is linked to asthma.